Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CERVIX UTERI”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed2000

Determination of the cellular retinoic-acid-binding protein in dysplastic epithelia of the cervix uteri, differentiated into apo and holo forms.

PURPOSE: The appearance of the cervical mucosa is regulated by different factors including retinoic acid. Hormone-dependent alteration of the cervix uteri mucosa is accompanied by a decrease or increase of cytoplasmatic retinoic-acid-binding protein (CRABP). To elucidate whether this hormone-dependent alteration of CRABP is preserved in the case of neoplasms of the cervix uteri, we measured the level of total and apo-CRABP in normal and neoplastically transformed cervical cells. METHODS: In a prospective pilot study, standardised biopsies of normal epithelium and cervical intra-epithelial neoplasm grade 3 (CIN III) were taken from 24 patients. A newly developed method was used to determine the intra-epithelial level of apo- and total CRABP. RESULTS: The concentration of total CRABP in normal squamous epithelium compared with that in intra-epithelial neoplasm grade 3 is very significantly lower in the CIN III areas (normal: 3.66 +/- 1.46 pmol/ mg wet weight +/- SD; CIN III 1.43 +/- 0.59 pmol/mg P < 0.01). In addition CRABP in the apo form is lower in normal than in neoplastic epithelium (Wilcoxon test for paired non-parametric values: P < 0.05; mean for all patients: normal: 1.65 + 0.82 pmol/mg; CIN III: 1.14 +/- 0.23 pmol/mg). CONCLUSION: From our results we conclude that, in neoplastically transformed cells, the hormone-dependent CRABP cycle is interrupted. Whether this has consequences for the further development of the neoplastic cells has to be elucidated.

Cervix Uteri↗
PubMedDate not supplied

[The morphological characteristics of a papillomavirus infection in the epithelial tissue of the cervix uteri in comparison with the data from the molecular biological identification of specific HPV DNA sequences].

Summarized cytomorphologic, molecular-biological data and the analysis results of cervix uteri multilayer squamous epithelium cells mitotic regime in benign (104 observations) and dysplastic (101 observations) processes, including 6/11 and 16/18 types DNA HPV, are presented in the paper. It has been shown that the use of HPV-infection morphologic markers as compared with cell mitotic activity and with in situ hybridization results allows one to determine the obvious virus role in the induction of flat, acute and papillar condylomas, as well as of cervix uteri dysplastic processes. To ascertain the prognosis of development of dysplasia associated with HPV DNA of 6/11 and 6/18 types, the increase of mitosis pathological forms and of their arrangement zones in epithelium layer parallel with gravity increase of three-group, multipolar and K mitosis should be considered a reliable marker of high oncogenic risk.

Biomarkers↗
PubMed2003

p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations.

p16 is a tumor suppressor gene that plays a central role in the regulation of the cell cycle. In squamous cervical cancers, overexpression of p16 is induced by HPV and associated with the carcinogenesis of cervical epithelia. The aim of this study was to determine whether immunostaining of p16 is useful in detecting adenocarcinomas of the cervix uteri in histologic and cytologic routine specimens. A total of 45 surgical specimens, including 18 cases of invasive carcinoma, 8 cases of adenocarcinoma in situ, 4 cases of endocervical glandular atypia (cervical glandular intraepithelial neoplasia), and 15 reactive lesions of the endocervical glands were immunostained using a specific anti-human p16 monoclonal antibody (clone E6H4, mtm laboratories AG, Heidelberg, Germany). Furthermore, immunocytochemical analysis was performed on 10 preoperative ThinPrep cytologic samples with abnormal glandular cells and compared with the human papillomavirus status as assessed with the Hybrid Capture II test. p16 was detected immunohistochemically in all 26 cases of adenocarcinoma of the cervix uteri, including 18 invasive and 8 in situ carcinomas. Only a focal expression was evidenced in the four specimens with endocervical glandular atypia, and no reaction was found in reactive lesions. Also, the immunocytochemical analysis on the 10 ThinPrep specimens evidenced a strong expression of p16 in neoplastic endocervical cells. In all cases this was associated with a high-risk HPV-positive typing. p16 is a useful marker for the detection of the adenocarcinoma of the cervix uteri and its precursors. The immunocytochemical detection on ThinPrep specimens may contribute to an early detection of endocervical lesions.

Adenocarcinoma↗
PubMed1988

Effect of hyperthermia on the frequency of sister-chromatid exchanges in patients with cancer of cervix uteri.

The frequencies of sister-chromatid exchanges (SCE) were studied in patients with cancer of the cervix uteri and normal controls at 37 degrees C and 40 degrees C. At 37 degrees C the mean frequency of SCE was found to be 8.26 +/- 1.91 in untreated patients with cervical cancer and 7.91 +/- 1.68 in cancer patients treated with radiotherapy; these values were significantly higher than the control value of 5.34 +/- 1.28 exchanges. Increase of the growth temperature to 40 degrees C elevated the SCE frequency to 11.95 +/- 2.12 in patients without radiotherapy treatment, 13.37 +/- 2.17 in patients with radiotherapy treatment and 7.82 +/- 1.84 in normal controls. These data indicate that there is a differential induction of SCEs by hyperthermia in the lymphocytes of control women and patients with cancer of the cervix uteri.

Adult↗
PubMed1989

Prognosis of the adenocarcinoma of the cervix uteri: a comparative study.

The different prognoses for patients with adenocarcinomas and squamous cell carcinomas of the cervix uteri were proved by matched-pair analysis. One hundred forty-four patients with adenocarcinoma treated in 1964-1985 were compared in a ratio of 1:2 with 268 patients with squamous cell carcinoma comparable in age, stage, and treatment modality. In both groups 45% of patients were in stage I, 38% in stage II, 15% in stage III, and 2% in stage IV. Five- and 10-year survivals of patients with adenocarcinoma were significantly lower than for those with squamous cell carcinoma (53% resp. 42% vs 68% vs 58%, P = 0.006). In an analyses of patients' prognosis according to clinical stage there was no significant difference between both groups in stages III and IV treated exclusively by radiotherapy. No significant differences were found in stage I and II patients treated by radical surgery. However, the most significant difference in prognosis was seen in stage I and II patients treated by radiotherapy. Five-year survival was 58.6% in stage I adenocarcinomas compared with 85.0% in squamous cell carcinomas. It can be concluded from these results that a discussion of the problem of FIGO staging is more necessary than a discussion of the different radiosensitivities of these two histological types. Surgical treatment must have the same priority as radical surgery or staging laparotomy for exact histologic staging in adenocarcinomas of the cervix uteri.

Adenocarcinoma↗
PubMed1976

Carcinoma in situ of the cervix uteri in pregnancy.

After reviewing the charts of patients at the Tulane Unit of Obstetrics and Gynecology of Charity Hospital between the years 1950 and 1970, 25 patients were noted to have carcinoma in situ of the cervix uteri associated with pregnancy. Twenty-two patients had positive Papanicolaou smears. Subsequently, 20 patients had conization of the cervix uteri to exclude an invasive lesion. Vaginal delivery was accomplished in 17 of the patients. After complete re-evaluation, definite treatment was done six to eight weeks post partum, and there were no recurrences or deaths from the disease.

Adult↗
PubMed1975

Frequency and management of urological and some other complications following radical surgery for carcinoma of the cervix uteri, stages I and II.

A series of 202 patients with stage I and II carcinoma of the cervix uteri is presented. Radical hysterectomy and pelvic lymph node dissection was performed in all cases and most patients received radiotherapy in addition. The condition at 5-year follow-up of all patients is reported and the facts associated with operative complications are analysed. Special attention was paid to the urological condition by performing urographies as a routine study both pre- and postoperatively. There was a strong correlation between the pathological postoperative urologic finding in regard to poor prognosis and permanent complications. Urinary tract infections occurred frequently and were difficult to handle. The operations performed for urological complications are listed. It is concluded that the treatment of carcinoma of the cervix uteri should be concentrated on clinics with a well-trained staff. At every stage of treatment intensive teamwork is most important. The rate of complications can be reduced by intensifying studies especially in the postoperative period. New diagnostic procedures and prophylactic measures should be tried andintroduced into routine practice if proved valuable. It is important that major surgery, such as radical hysterectomy, be performed in a teaching hospital for gynecologists.

Adenocarcinoma↗
PubMed1984

[Radiotherapy of cancer of the stump of the cervix uteri].

The paper is concerned with the results of combined radiotherapy provided to 68 patients with cancer of the cervix uteri stump. An impossibility of homogenous irradiation of the whole affected organ due to its anatomic specificities during intracavitary gamma-therapy following the prior supravaginal amputation of the uterus results in a dose deficiency in the cupola of the cervix uteri stump which should be made up for by gamma-beam therapy. It makes it possible to achieve the 5-year survival in 81.8% of patients.

Adult↗
PubMedDate not supplied

[Ionization of the cervix uteri].

A procedure of copper ionization of the cervix uteri performed in 1054 cases of chronic cervicitis is described. This way of treatment resulted in the reduction of exaggerated cervical discharge, the volume of the cervix was diminished, and erosions became smaller. Slight bleeding after this therapy was recorded as complication in two cases. In 85% of cases only one ionization is needed to reach the optimal therapeutic effect.

Chronic Disease↗
PubMedDate not supplied

The cytologic diagnosis of adenocarcinoma in situ of the cervix uteri and related lesions. I. Adenocarcinoma in situ.

Seventy cases of histologically confirmed adenocarcinoma in situ (AIS) of the cervix uteri have been predicted in this laboratory using cytologic criteria, which are illustrated in this paper. The architectural features that were of primary diagnostic importance included an exfoliation pattern consisting of sheets of cells and tissue fragments in the form of cellular strips and rosettes. Nuclear criteria allowed the distinction of AIS into well-differentiated and poorly differentiated types. The former showed nuclear enlargement, an oval nuclear shape, hyperchromasia and moderate-to-coarse granularity as usual features. In the latter, nuclear enlargement was even greater, with an oval-to-round shape, prominent nucleoli and chromatin that was usually only finely granular. Variant patterns of AIS included endocervical, endometrioid and intestinal subtypes, each with characteristic cytologic appearances that correspond closely with their histologic appearances. The evolution of the description of AIS reveals a range of precursor lesions that may match the range of invasive adenocarcinomas originating in the cervix. This suggests that invasive adenocarcinoma of the cervix uteri could be preventable as is its more common squamous counterpart.

Adenocarcinoma↗
PubMed2001

[Primary malignant melanoma of the cervix uteri: apropos of 1 case with review of the literature].

The authors report a case of malignant melanoma of the cervix uteri diagnosed in a young 35-year-old patient. Isolated genital bleeding was the beginning symptom. The physical exam showed a cervical dark tumor, with extension into the vagina (superior third), the parametrium was free. Cervical biopsy concluded to a malignant melanoma. No other abnormalities were observed and the tumor was classed stage IIA-FIGO. A total hysterectomy with bilateral annexectomy and pelvic lymphadenectomy was performed. In the way, the patient died after ten months by local and general recurrence. Primitive malignant melanoma of the cervix uteri is rare. Only 39 cases are reported in literature at this day. It is usually initially misdiagnosed mainly in the achromic forms, then the immuno-histochemical study is useful. Its treatment is not well codified and its histogenesis was controversial for a long time.

Adult↗